• Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas

  • Volition Appoints Dr. Phillip Barnes to Board of Directors

  • Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes

  • VolitionRx Limited Announces Second Quarter 2019 Financial Results and Business Update

  • Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer

  • VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update

  • Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock

  • VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China

  • VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding

  • VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update

  • VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer

  • VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update

  • VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report

  • VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics

  • VolitionRx Limited Extends Clinical Trial Program in Lung Cancer

  • VolitionRx Limited Signs Memorandum of Understanding with Fosun Long March in China

  • VolitionRx Limited to Present at Conferences in March & April 2019

  • VolitionRx Limited to Present at Conferences in the U.S. Next Week

  • VolitionRx Limited Announces Full Fiscal Year 2018 Financial Results and Business Update

  • VolitionRx Limited Schedules Full Year 2018 Earnings Conference Call and Business Update

arrow-downarrow-leftarrow-rightarrowchevron-downcircle-link--redcircle-linkcloseplayplus